Beam Therapeutics shares are trading higher after HC Wainwright & Co. initiated coverage on the stock with a Buy rating and announced an $80 price target.
Portfolio Pulse from Benzinga Newsdesk
Beam Therapeutics shares are trading higher after HC Wainwright & Co. initiated coverage on the stock with a Buy rating and announced an $80 price target.
July 23, 2024 | 2:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Beam Therapeutics shares are trading higher following HC Wainwright & Co.'s initiation of coverage with a Buy rating and an $80 price target.
The initiation of coverage with a Buy rating and a high price target by a reputable firm like HC Wainwright & Co. is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100